Glycodeoxycholic Acid-d4
(Synonyms: 甘氨脱氧胆酸 d4) 目录号 : GC47411
An internal standard for the quantification of glycodeoxycholic acid
Cas No.:1069132-37-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Glycodeoxycholic acid-d4 is intended for use as an internal standard for the quantification of glycodeoxycholic acid by GC- or LC-MS. Glycodeoxycholic acid (GDCA) is a glycine-conjugated form of the secondary bile acid deoxycholic acid .1 It induces a reversible, concentration-dependent reduction in myogenic tone in rats and decreases expression of the gene encoding the cytochrome P450 (CYP) isoform 7A1 (CYP7A1) in rabbits.2,3 Serum levels of GDCA are elevated in non-surviving patients with acetaminophen-induced acute liver failure (AALF) compared with survivors.4 GDCA levels are also increased in the plasma of patients with asthma.5
1.Lefebvre, P., Cariou, B., Lien, F., et al.Role of bile acids and bile acid receptors in metabolic regulationPhysiol. Rev.89(1)147-191(2009) 2.Khurana, S., Raina, H., Pappas, V., et al.Effects of deoxycholylglycine, a conjugated secondary bile acid, on myogenic tone and agonist-induced contraction in rat resistance arteriesPLoS One7(2)e32006(2012) 3.Shang, Q., Guo, G.L., Honda, A., et al.Bile acid flux through portal but not peripheral veins inhibits CYP7A1 expression without involvement of ileal FGF19 in rabbitsAm. J. Physiol. Gastrointest. Liver Physiol.307(4)G479-G486(2014) 4.Woolbright, B.L., McGill, M.R., Staggs, V.S., et al.Glycodeoxycholic acid levels as prognostic biomarker in acetaminophen-induced acute liver failure patientsToxicol. Sci.142(2)436-444(2014) 5.Comhair, S.A.A., McDunn, J., Bennett, C., et al.Metabolomic endotype of asthmaJ. Immunol.195(2)643-650(2015)
| Cas No. | 1069132-37-1 | SDF | |
| 别名 | 甘氨脱氧胆酸 d4 | ||
| Canonical SMILES | C[C@H](CCC(NCC(O)=O)=O)[C@@]1([H])CC[C@@]2([H])[C@]3([H])CC[C@]4([H])C([2H])([2H])[C@H](O)C([2H])([2H])C[C@]4(C)[C@@]3([H])C[C@H](O)[C@@]21C | ||
| 分子式 | C26H39D4NO5 | 分子量 | 453.7 |
| 溶解度 | DMSO : 125 mg/mL (275.54 mM; ultrasonic and warming and heat to 60°C) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.2041 mL | 11.0205 mL | 22.041 mL |
| 5 mM | 0.4408 mL | 2.2041 mL | 4.4082 mL |
| 10 mM | 0.2204 mL | 1.102 mL | 2.2041 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet